IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026
Key Highlights
- ➤IceCure (ICCM) will report nine-month 2026 results November 18 before Nasdaq opens
- ➤Conference call scheduled November 18 at 10:00 a.m. EST
- ➤ProSense is FDA-cleared for localized breast cancer treatment in patients aged 70 and older
IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 PR Newswire
CAESAREA, Israel, Nov. 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2026 before the Nasdaq Stock Market opens on Wednesday, November 18, 2026. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day.
Get started
Create a free account to read the full story.